Physician profile
Kiran Devaraj
NPI 1952544652
$13,104.80
in general payments reported to CMS, 2019-2025
20 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,151 · 2020: $520 · 2021: $113 · 2022: $145 · 2023: $376 · 2024: $4,805 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,160 · Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,159.83 |
| Food and Beverage | $2,015.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,912.53 | 2023-2025 | Evera Mri Xt Dr Surescan, Affera Mapping System, Pulseselect |
| Abbott Laboratories | $4,520.43 | 2019-2025 | Aveir |
| Medtronic Vascular, INC. | $1,737.79 | 2019 | |
| Biosense Webster, INC. | $434.12 | 2019-2022 | |
| Pfizer INC. | $290.99 | 2019-2020 | |
| Amgen INC. | $263.10 | 2019-2020 | |
| Astellas Pharma US INC | $255.26 | 2019 | |
| Atricure, INC. | $175.95 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Novartis Pharmaceuticals Corporation | $138.08 | 2019-2020 | |
| Neos Therapeutics, LP | $96.31 | 2022-2023 | Adzenys Xr-Odt |
| Boston Scientific Corporation | $70.01 | 2025 | Accolade Sr |
| Janssen Pharmaceuticals, INC | $49.58 | 2020 | |
| Philips North America LLC | $39.84 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $26.03 | 2019-2020 | |
| Lundbeck LLC | $19.80 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $18.30 | 2019 | |
| Amarin Pharma, INC. | $17.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.86 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Devaraj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.